ArticleCureus2025
Incidental Prostate Cancer Detected in Holmium Laser Enucleation of the Prostate (HoLEP) Specimens: A Single-Center Experience.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncidental prostate cancer (iPCa) is an unsuspected malignancy found in tissue resected for benign prostatic hyperplasia (BPH). We evaluated the prevalence and characteristics of iPCa among patients undergoing holmium laser enucleation of the prostate (HoLEP) at our center.
methodsWe retrospectively reviewed 259 consecutive HoLEP cases. Patients with known prostate cancer before surgery were excluded from iPCa rate calculations. Demographics, prostate-specific antigen (PSA), prostate volume, and histopathology were recorded. Between-group comparisons were performed using the Mann-Whitney U test and the chi-square test (p < 0.05).
resultsiPCa was identified in 37/259 (14.3%) cases. Gleason distribution among iPCa was 3+3=6 in 23/37 (62.2%), Gleason 7 in 9/37 (24.3%) (3+4=7 in eight; 4+3=7 in one), Gleason 8-10 in 4/37 (10.8%), and not assigned in 1/37 (2.7%). Patients with iPCa were slightly older (median age, 75 years) than those with benign histology (median age, 72 years; p=0.014). Median PSA (7.85 vs. 7.20 ng/mL; p=0.45), prostate volume (112.5 vs. 120 cc; p=0.25), PSA density (0.069 vs. 0.061 ng/mL/cc; p=0.29), and proportions with PSA>10 ng/mL (11/37 (29.7%) vs. 65/222 (29.3%); p=0.998) or prostate volume >100 cc (23/37 (62.2%) vs. 147/222 (66.2%); p=0.891) did not differ significantly.
conclusionApproximately one in seven HoLEP patients (37/259, 14.3%) had iPCa, predominantly of the low-grade (23/37, 62.2%) type. Most cases were suitable for conservative management; only 4/259 (1.5%) of the entire cohort had incidentally detected high-grade (Gleason ≥8) disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.